#Healthcare #Prevention #CardiometabolicHealth #CKMSyndrome #PublicHealth #ChronicDisease #AHA #Innovation #TeamCare Hypertension is now recognized as a metabolic risk factor within the cardiovascular-kidney-metabolic (CKM) syndrome framework
Second and decisively those trials underpin an approved product with a defined label, which no CagriSema trial does
However, taken together, the above highlights the importance of individualized treatment approaches
A disproportionality analysis (Godfrey et al., JEADV 2025) found a reporting odds ratio of 1.73 for tirzepatide (95% CI: 1.42 to 2.09), and as high as 2.46 for semaglutide
However, higher OSA severity was associated with lower GLP-1 response to glucose, after adjusting for BMI, sex, and glycaemic condition ( p = 0.045)
It supports gut health and metabolic function beyond just appetite suppression